PARIS, FRANCE: Nanobiotix, a biotechnology company developing nanotherapeutics for cancer, has announced a global deal with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for its lead drug NBTXR3.
NBTXR3 is a potential first-in-class radioenhancer that is being tested in several solid tumor indications, including a global Phase 3 study in head and neck cancer and a Phase 2 study in lung cancer. NBTXR3 is also being evaluated in combination with immune checkpoint inhibitors for metastatic cancers.
Under the deal, Nanobiotix will grant Janssen a worldwide license for NBTXR3, excepting territories previously licensed to LianBio. Nanobiotix will receive up to $60 million in near term cash and operational support, and up to $1.8 billion in potential development, regulatory, and sales milestones. Nanobiotix will also receive tiered double-digit royalties on net sales of NBTXR3.
Nanobiotix will maintain operational control of the ongoing studies and NBTXR3 manufacture and supply. Janssen will be fully responsible for the lung cancer study and will have the right to assume control of other studies. The deal also includes a framework for additional potential milestone payments for five new indications that may be developed by Janssen or Nanobiotix.
Nanobiotix is also eligible to receive up to $30 million in equity investments from Johnson & Johnson Innovation – JJDC, Inc.
Nanobiotix said the deal will enable it to reach millions of patients around the world with its innovation in oncology and to collaborate with Janssen to accelerate the development and commercialization of NBTXR3.
Nanobiotix announces key development milestones for 2021 after successful Nasdaq IPO